REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
8.93
+0.83 (10.25%)
At close: Aug 13, 2025, 4:00 PM
8.55
-0.38 (-4.25%)
After-hours: Aug 13, 2025, 5:44 PM EDT
REGENXBIO Employees
REGENXBIO had 353 employees as of December 31, 2024. The number of employees increased by 9 or 2.62% compared to the previous year.
Employees
353
Change (1Y)
9
Growth (1Y)
2.62%
Revenue / Employee
$441,309
Profits / Employee
-$497,368
Market Cap
451.09M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RGNX News
- 5 days ago - REGENXBIO Inc. (RGNX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights - PRNewsWire
- 6 days ago - REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy - PRNewsWire
- 13 days ago - REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights - PRNewsWire
- 4 weeks ago - REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy - PRNewsWire
- 2 months ago - Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome - Seeking Alpha
- 2 months ago - Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer - Benzinga
- 2 months ago - REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 - PRNewsWire